Tag Archives: Axovant

Alkermes, ALKS5461, and the FDA

Alkermes late yesterday announced that the third of the ALKS 5461 antidepressant Phase III trials had yielded positive results for the high dose, utilizing an SPCD trial design and an alternative parsing of the MADRS as the primary endpoint. The … Continue reading

Posted in Biotech, Muddled Media | Tagged , , , , , , | Leave a comment

FRM-6124 Trials Halted

There is a highly credible report that the Forum Pharmaceuticals Phase III trials for encenicline/FRM-6124 are being halted due to a safety issue: Gastric hypomotility setting the stage for eventual gut perforation. FRM-6124 is a program that NIR has long … Continue reading

Posted in Biotech, Science | Tagged , , , , , | 1 Comment

Mountains and Molehills

First, the Mountain: Denali Therapeutics made their May debut with the announcement that they raised $217 million in a Series A, a very dynamic bit of BioTheatre. Indeed, it is as compelling a headline as we have seen thus far … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , | 1 Comment